Table 2.
Multivariable models of variables associated with endocrine initiation among women tested by Oncotype Dx (N = 1528) and women who were eligible for testing by Oncotype Dx (N = 4674)
| Oncotype Dx-tested | Oncotype Dx-eligible | ||||||
|---|---|---|---|---|---|---|---|
| OR | (95% CI) | P | OR | (95% CI) | P | ||
| Recurrence score | 0.02 | ||||||
| Low (ref) | |||||||
| Intermediate | 0.98 | (0.64–1.50) | |||||
| High | 0.40 | (0.20–0.81) | |||||
| Tested | <0.001 | ||||||
| Yes | 2.48 | (2.03–3.04) | |||||
| No (ref) | |||||||
| Year diagnosed | 0.13 | 0.004 | |||||
| 2006–2007 (ref) | |||||||
| 2008–2009 | 0.74 | (0.49–1.13) | 0.74 | (0.61–0.89) | |||
| 2010–2012 | 1.17 | 0.65–2.09) | 0.89 | (0.70–1.15) | |||
| Age at diagnosis | 0.20 | <0.001 | |||||
| 24–39 | 0.49 | (0.24–1.01) | 0.59 | (0.43–0.82) | |||
| 40–49 | 0.73 | (0.48–1.11) | 0.74 | (0.60–0.90) | |||
| 50–59 (ref) | |||||||
| 60–63 | 0.80 | (0.49–1.30) | 1.01 | (0.80–1.27) | |||
| Race-ethnicity | 0.06 | 0.19 | |||||
| NH white (ref) | |||||||
| NH black | 3.62 | (0.83–15.81) | 0.92 | (0.61–1.38) | |||
| Hispanic | 0.62 | (0.27–1.41) | 0.89 | (0.60–1.33) | |||
| Other | 2.52 | (0.89–7.13) | 1.44 | (1.01–2.06) | |||
| Marital status | 0.16 | 0.12 | |||||
| Married (ref) | |||||||
| Not married | 0.76 | (0.52–1.11) | 0.87 | (0.72–1.04) | |||
| Prior cancer | 0.65 | 0.84 | |||||
| No (ref) | |||||||
| Yes | 1.21 | (0.52–2.80) | 1.04 | (0.71–1.53) | |||
| State | 0.004 | ||||||
| CA (ref) | |||||||
| GA | 0.62 | (0.32–1.20) | 1.15 | (0.85–1.55) | |||
| KY | 1.73 | (0.72–4.14) | 1.71 | (1.19–2.47) | |||
| NY | 1.05 | (0.50–2.19) | 1.60 | (1.16–2.20) | |||
| OH | 1.20 | (0.58–2.50) | 1.45 | (1.05–2.00) | |||
| Area | 0.74 | 0.70 | |||||
| Rural (ref) | |||||||
| Urban | 1.17 | (0.47–2.92) | 1.08 | (0.74–1.56) | |||
| Median household income | 0.24 | 0.07 | |||||
| 1 (lowest (ref)) | |||||||
| 2 | 1.23 | (0.68–2.22) | 0.96 | (0.74–1.26) | |||
| 3 | 1.00 | (0.57–1.76) | 0.97 | (0.74–1.26) | |||
| 4 | 1.84 | (0.97–3.49) | 1.35 | (1.02–1.82) | |||
| 5 (highest) | 1.10 | 0.59–2.07) | 1.01 | (0.75–1.36) | |||
| Stage | 0.14 | 0.52 | |||||
| I (ref) | |||||||
| II | 0.71 | (0.45–1.12) | 0.92 | (0.71–1.19) | |||
| Nodal involvement | 0.22 | 0.10 | |||||
| N0 | 0.42 | (0.14–1.26) | 0.87 | (0.64–1.17) | |||
| N1mic | 0.69 | (0.18–2.62) | 1.40 | (0.91–2.17) | |||
| N1 (ref) | |||||||
| HER2 status | 0.82 | 0.33 | |||||
| Negative | 0.89 | (0.49–1.62) | 1.21 | (0.55–2.92) | |||
| Borderline | 0.63 | (0.13–3.06) | 1.26 | (0.94–1.56) | |||
| Unknown (ref) | |||||||
| Hormone receptor status | <0.001 | ||||||
| ER and PR both positive (ref) | |||||||
| Only ER or PR positive | 0.80 | (0.45–1.42) | 0.58 | (0.47–0.72) | |||
| Histological grade | 0.52 | <0.001 | |||||
| 1–2 (well/moderately differentiated (ref) | |||||||
| 3 (poorly or not differentiated) | 1.18 | (0.71–1.96) | 0.68 | (0.56–0.84) | |||
| One year comorbidities | 0.57 | 0.51 | |||||
| 0 (ref) | |||||||
| 1 or more | 0.86 | (0.52–1.43) | 0.92 | (0.72–1.18) | |||
| Surgery type | 0.74 | 0.42 | |||||
| Breast-conserving surgery (ref) | |||||||
| Mastectomy | 0.94 | (0.47–2.92) | 0.93 | (0.78–1.11) | |||
| Chemotherapy | 0.10 | ||||||
| No (ref) | |||||||
| Yes | 1.49 | (0.92–2.39) | |||||
| Chemotherapy | Tested | <0.001 | |||||
| No | Yes | -- | 3.25 | (2.53–4.16) | |||
| No | -- | ||||||
| Yes | Yes | -- | 1.35 | (0.96–1.90) | |||
| No | -- | ||||||
Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor